| Study |
|
Exclusion reasons |
Remarks |
Reference(s) |
|
|
Ahn, 2020
|
-
|
|
|
Ahn J. Korean Med. Sci. 2020; 35:e149 10.3346/jkms.2020.35.e149
|
|
|
Shen, 2020
|
-
|
|
|
Shen C JAMA 2020 Mar 27;323(16):1582-1589. 10.1001/jama.2020.4783
|
|
|
O'Brien (Part A: uninfected household contacts), 2021
|
randomized controlled trial
|
|
< Study carried out before the release of the omicron variant >
|
O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569 O'Brien MP et al. New England Journal of Medicine 10.1056/NEJMoa2109682 O?Brien MP et al. medRxiv 10.1101/2021.06.14.21258567
|
|
|
O'Brien (Part B: recently infected asymptomatic patients), 2021
|
randomized controlled trial
|
|
|
O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569
|
|
|
Ye, 2020
|
-
|
no control group
|
|
Ye J. Med. Virol. 2020; : 10.1002/jmv.25882
|
|
|
Zhang, 2020
|
-
|
no control group
|
|
Zhang Chest 2020; : 10.1016/j.chest.2020.03.039
|
|
|
Zhang, 2020
|
-
|
no control group
|
|
Zhang L Aging (Albany NY) 2020 Apr 22;12(8):6536-6542. 10.18632/aging.103102
|
|
|
CT-P59 1.2, 2020
|
randomized controlled trial
|
no clinically relevant endpoint
|
preliminary unpublished results extracted from the EMA review document. < Study carried out before the release of the omicron variant >
|
|
|
|
Bargay-Lleonart, 2022
|
randomized controlled trial
|
no clinically relevant endpoint
|
The trial was terminated early due to the impossibility of recruitment due to the pandemic.
|
Bargay-Lleonart J J Clin Med 2022 May 27;11(11):3039. 10.3390/jcm11113039
|
|
|
Dai W, 2020
|
retrospective cohort
|
other
|
inadequate statistical analysis
|
Wei Dai, Jian Wu, Tianfu Li, Jiawei Shen, Rongrong Pang, Bangshun He, Tao Luo, Yanju Guo, Yang Yang, Jun Zhao, Mingchao Zhang, Na Li, Ying Han, Qiuyue Wu, Weiwei Li, Xinyi Xia BMC Cardiovascular Diabetology
|
|
|
Isa, 2021
|
randomized controlled trial
|
other
|
Phase I: multiple-dose administration of REGEN-COV.
|
Isa F et al. medRxiv 10.1101/2021.11.10.21265889
|
|
